Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03127631 · ClinicalTrials.gov registry record · NA

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

A NA study of Prostate Cancer and Cardiovascular Disease, sponsored by McMaster University.

Recruiting
Registry status
NA
Development phase
6,000
Enrollment target
20
Study locations

NCT03127631: Recruiting NA study of Prostate Cancer and Cardiovascular Disease, sponsored by McMaster University.

NCT03127631 is a NA study of Prostate Cancer and Cardiovascular Disease that is actively recruiting participants, run by McMaster University. The registered enrollment target is 6,000 participants, above the 600-participant average among 735 other Prostate Cancer trials with a reported enrollment target (900% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03127631, a NA study of Prostate Cancer and Cardiovascular Disease, is actively recruiting participants, sponsored by McMaster University.

RECRUITING
Registry status
NA
Development phase
6,000 participants
Enrollment target
20
Study locations

Study Summary

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

Primary Outcome

Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).

Conditions Studied

Prostate Cancer Cardiovascular Disease

Interventions

  • BEHAVIORAL Exercise
  • BEHAVIORAL Nutrition
  • BEHAVIORAL Smoking cessation
  • DRUG Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
  • DRUG ACE inhibitor

Study Locations (20)

Rio Grande do Sul

  • Hospital de Caridade de Ijuí - Ijuí
  • Hospital de Clínicas de Porto Alegre - Porto Alegre
  • Irmandade Da Santa Casa De Misericórdia De Porto Alegre - Porto Alegre
  • Hospital Mae de Deus - Porto Alegre

Paraná

  • Sociedade Hospitalar Angelina Caron - Campina Grande do Sul
  • Nucleo de Pesquisa Clinica Hospital do Rocio - Campo Largo
  • Centro Médico São Francisco - Curitiba

São Paulo

  • Hospital Municipal de Barueri - Barueri
  • Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP - Botucatu
  • Hospital Universitário São Francisco na Providência de Deus - Bragança Paulista

South Australia

  • Royal Adelaide Hospital - Adelaide
  • Flinders Medical Center - Adelaide

Minas Gerais

  • Hospital Felício Rocho - Belo Horizonte
  • Universidade Federal do Triângulo Mineiro - Uberaba

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Kansas

  • University of Kansas Medical Center - Kansas City

New South Wales

  • Westmead Hospital - Westmead

Trial Details

FieldValue
Enrollment Target 6,000 participants
Start Date 2015-10-21
Est. Completion 2026-12
Phase NA
McMaster University

31 total trials

What NCT03127631 shows while recruiting

NCT03127631 is an interventional study that assigns participants to a tested intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 600-participant average among 735 other Prostate Cancer trials with a reported enrollment target (900% higher).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Exercise is the first listed.

NCT03127631 names 20 study sites across 11 states, led by Rio Grande do Sul, Paraná, São Paulo.

Frequently Asked Questions

What is clinical trial NCT03127631 about?

NCT03127631 is a clinical study titled "A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients". RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

What is the current status of trial NCT03127631?

This trial is currently recruiting. It is a NA study. The enrollment target is 6,000 participants. The study started on 2015-10-21. Estimated completion is 2026-12.

What conditions does trial NCT03127631 study?

This clinical trial studies the following conditions: Prostate Cancer, Cardiovascular Disease.

What interventions are being tested in trial NCT03127631?

The interventions under investigation include: Exercise (BEHAVIORAL), Nutrition (BEHAVIORAL), Smoking cessation (BEHAVIORAL), Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) (DRUG), ACE inhibitor (DRUG).

Who is sponsoring clinical trial NCT03127631?

This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03127631 being conducted?

This trial has 20 study locations across Georgia, Kansas, New South Wales, South Australia, Federal District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03127631's enrollment target sits among peer trials

6,000 10th of 735 higher than 726 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00005095 · 6,000 participants

    Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

  • NCT00280202 · 6,000 participants

    Detection of Genetic Markers of Lung Cancer

  • NCT03539705 · 6,000 participants

    Food Allergy Registry at a Single Site

  • NCT04324619 · 6,000 participants · NA

    iLookOut for Child Abuse: Micro-learning to Improve Knowledge Retention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03127631

Source: ClinicalTrials.gov NCT03127631, the US trial registry maintained by the National Library of Medicine. NCT03127631 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.